youtube_live
Q3 2026 earnings • in 2 days
See detailschevron_right
ONC:NASDAQ
BeOne Medicines AG
$361.27
arrow_downward
-2.45%(-9.06) 1D
$361.27
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 2, 4:00:01 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ONC...
Open
$365.29
High
$370.10
Low
$360.88
Mkt. cap
44.58B
Avg. vol.
382.67K
Volume
0.00
52-wk high
$388.66
52-wk low
$253.95
Beta
0.61
Shares outstanding
109.79M
No. of employees
12K
Open
$365.29
High
$370.10
Low
$360.88
Mkt. cap
44.58B
Avg. vol.
382.67K
Volume
0.00
52-wk high
$388.66
52-wk low
$253.95
Beta
0.61
Shares outstanding
109.79M
No. of employees
12K
News stories
From web sources and news partners
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12K
FoundedOct 28, 2010
Headquarters-
SectorBiotechnology
Websitebeonemedicines.com
Analyst ratings
Based on 13 analysts giving stock ratings to ONC in the past 3 months
Strong buy
Buy
13
Hold
0
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for ONC in the last 3 months.
Highest
Current $361.27
$466.00 (+28.99%)
Average
$427.25 (+18.26%)
Lowest
$370.00 (+2.42%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Leonid Timashev RBC Capital | Buy | Maintained | $459.00 | +27.1% | 10/27/2026 |
Yigal Nochomovitz Citi | Buy | Maintained | $466.00 | +29% | 10/19/2026 |
Sean Laaman Morgan Stanley | Buy | Reiterated | $425.00 | +17.6% | 10/16/2026 |
Derek Archila Wells Fargo | Buy | Maintained | $400.00 | +10.7% | 10/16/2026 |
Gregory Renza Truist Financial | Buy | Maintained | $420.00 | +16.3% | 10/08/2026 |
Jessica Fye J.P. Morgan | Buy | Maintained | $445.00 | +23.2% | 10/01/2026 |
Etzer Darout Barclays | Buy | Maintained | $415.00 | +14.9% | 09/10/2026 |
Kalpit Patel Wolfe Research | Buy | Reiterated | $370.00 | +2.4% | 08/09/2026 |
Jill Wu CMB International Securities | Buy | Maintained | $442.31 | +22.4% | 08/07/2026 |
David Li Bank of America Securities | Buy | Reiterated | $423.00 | +17.1% | 08/06/2026 |
Yanan Zhu Wells Fargo | Buy | Maintained | $400.00 | +10.7% | 08/06/2026 |
Michael Schmidt Guggenheim | Buy | Maintained | $430.00 | +19% | 08/05/2026 |
Reni Benjamin Citizens JMP | Buy | Maintained | $405.00 | +12.1% | 08/06/2026 |
Yaron Werber TD Cowen | Buy | Maintained | $454.00 | +25.7% | 08/05/2026 |
Faisal Khurshid Jefferies | Buy | Upgraded | $380.00 | +5.2% | 07/12/2026 |
Unknown Analyst J.P. Morgan | Buy | Maintained | $415.00 | +14.9% | 05/20/2026 |
Unknown Analyst Leerink Partners | Buy | Maintained | $367.00 | +1.6% | 05/15/2026 |
Rebecca Liang Bernstein | Buy | Maintained | $412.00 | +14% | 03/18/2026 |
Next call in 2 days
Thu, Nov 5, 8:00 AM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $1.88
Revenue / Est. (USD)
- / 1.76B
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 1.41B | 1.50B | 1.51B | 1.71B |
Cost of goods sold | 196.51M | 142.42M | 167.22M | 174.53M |
Cost of revenue | 196.51M | 142.42M | 167.22M | 174.53M |
Research and development expenses | 523.66M | 615.42M | 541.22M | 612.28M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 529.00M | 555.29M | 555.10M | 593.21M |
Operating expense | 1.05B | 1.17B | 1.10B | 1.21B |
Total operating expenses | 1.25B | 1.31B | 1.26B | 1.38B |
Operating income | 163.11M | 185.04M | 249.90M | 325.05M |
Other non operating income | -4.76M | 4.16M | 14.54M | -2.68M |
EBT including unusual items | 147.16M | 149.24M | 259.22M | 312.46M |
EBT excluding unusual items | 160.80M | 189.96M | 259.22M | 309.33M |
Income tax expense | 22.32M | 82.74M | 31.86M | 75.45M |
Effective tax rate | 15.17% | 55.44% | 12.29% | 24.15% |
Other operating expenses | - | - | - | - |
Net income | 124.84M | 66.50M | 227.36M | 237.01M |
Net profit margin | 8.84% | 4.44% | 15.02% | 13.90% |
Earnings per share | 1.09 | 0.58 | 1.96 | 2.05 |
Interest and investment income | 13.79M | 32.37M | 27.66M | 27.90M |
Interest expense | -10.76M | -32.47M | -32.89M | -39.74M |
Net interest expenses | 3.03M | -103.00K | -5.22M | -11.84M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 198.86M | 219.47M | 289.30M | 363.97M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events